MT-II (Melanotan II) is a widely referenced melanocortin-receptor agonist used in neuroendocrine and pigmentation research. This guide covers what MT-II is, the receptors it engages, and how it should be handled in the laboratory. It is written for qualified researchers and contains no human-use, therapeutic, or dosing claims.
As a non-selective melanocortin agonist and the structural precursor to PT-141, MT-II sits at the center of a well-defined area of receptor pharmacology. The sections below cover its structure, the melanocortin system it acts on, the pathways most often studied, study-design considerations, handling, and documentation.
What Is MT-II?
MT-II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). Its cyclic structure improves stability and receptor engagement relative to the linear native hormone, and it acts as a non-selective agonist across several melanocortin receptor subtypes. It is supplied as a lyophilized powder for research use and reconstituted before laboratory application.
MT-II is also the structural precursor to PT-141 (bremelanotide), which was developed by modifying MT-II to shift its receptor-selectivity profile. This direct structural relationship makes the two compounds common subjects of comparative pharmacology studies, where researchers examine how specific modifications change receptor selectivity.
The Melanocortin System
The melanocortin system comprises five receptor subtypes (MC1R–MC5R) distributed across peripheral and central tissues. MC1R is associated with pigmentation pathways; MC3R and MC4R are associated with central-nervous-system signaling relevant to energy balance and neuroendocrine regulation; MC2R and MC5R have their own distinct roles. MT-II engages multiple subtypes non-selectively, which is precisely what makes it useful as a broad reference agonist when researchers dissect the contributions of individual receptors.
Because the native ligand α-MSH is short-lived, the cyclic, more stable MT-II provides a more practical experimental tool for probing melanocortin signaling in cell and animal systems.
Studied Mechanisms and Pathways
Pigmentation and Melanogenesis Research
Because MT-II activates MC1R, it is frequently used in melanogenesis (pigment-formation) research models, where investigators study the signaling cascades that regulate melanin production in melanocyte and animal systems. MC1R activation drives cAMP signaling that influences melanin synthesis, a pathway well suited to MT-II as a reference agonist.
Central Signaling via MC3R and MC4R
Through MC3R and MC4R engagement, MT-II is studied in central-signaling contexts, including appetite and energy-homeostasis pathways in preclinical models. MC4R in particular is expressed throughout the hypothalamus and limbic system and is implicated in energy balance and autonomic regulation, making MT-II a useful tool for probing these circuits.
Comparative Receptor Pharmacology
MT-II’s non-selective profile makes it a valuable comparator in receptor-selectivity studies. Placing MT-II alongside more selective analogs such as PT-141 lets researchers attribute observed effects to specific receptor subtypes and understand how structural modifications reshape selectivity.
Common Research Applications
- Melanogenesis research: MC1R-driven pigmentation signaling in cell and animal models.
- Neuroendocrine studies: MC3R/MC4R central signaling and energy-balance pathways.
- Comparative pharmacology: receptor-selectivity studies against PT-141 and other analogs.
- Receptor-binding characterization: agonist reference compound across melanocortin subtypes.
Research Considerations and Study Design
MT-II’s value as a broad reference agonist is also a design consideration: because it engages multiple receptors, experiments intended to isolate a single subtype need selective antagonists or knockdown controls to interpret results cleanly. Pairing MT-II with a more selective analog in the same design is a common way to separate subtype contributions.
As with other lyophilized peptides, purity and reconstitution practice affect reproducibility. Recording the batch COA and keeping reconstituted material within its stable window help ensure that receptor-response data reflect the compound rather than degradation artifacts.
Quality and Documentation
For melanocortin research, receptor-response data are only as reliable as the compound’s identity and purity. Research-grade MT-II should carry a batch-specific Certificate of Analysis confirming HPLC purity and identity. Alpha Tides PNW supplies MT-II 10mg as a research-grade compound with documentation available on request.
Recording COA identifiers alongside experimental notes creates a traceable link between receptor-pharmacology results and the exact material used.
MT-II and Melanocortin Drug Development
MT-II holds a notable position in melanocortin research history because it served as the structural starting point for PT-141 (bremelanotide). The development path from MT-II to PT-141 is a frequently cited example of how targeted structural modification can reshape a compound’s receptor-selectivity profile: by altering the parent molecule, researchers reduced MC1R-associated pigmentation activity while retaining engagement at MC3R and MC4R. Studying the two side by side therefore offers a clear, well-documented case study in structure-activity relationships within a single receptor family.
For this reason, MT-II is valued less as a selective probe and more as a broad reference agonist and a comparator. In receptor-pharmacology designs it provides a non-selective baseline against which more selective analogs can be measured, helping investigators map which downstream effects depend on which receptor subtypes. Its well-characterized, stable cyclic structure also makes it a dependable positive control in melanocortin assays. When MT-II is used in a study intended to isolate a single receptor’s contribution, pairing it with selective antagonists or a more selective analog such as PT-141 is the standard way to interpret the results cleanly.
Historical Development of Melanotan Compounds
MT-II belongs to a small family of synthetic melanocortin agonists that originated in research on alpha-melanocyte-stimulating hormone (α-MSH). Because the native α-MSH peptide is rapidly degraded, investigators sought more stable analogs that could serve as durable experimental tools for probing melanocortin signaling. The cyclic structure of MT-II was one outcome of that effort, providing improved metabolic stability and stronger receptor engagement than the linear parent hormone. This origin explains why MT-II is often encountered as a reference compound rather than a selective probe: it was designed for stability and broad activity, not subtype selectivity.
The subsequent modification of MT-II into PT-141 illustrates how the melanocortin field progressed from broad agonists toward compounds with narrower receptor profiles. Studying the lineage from α-MSH to MT-II to PT-141 gives researchers a compact, well-documented map of how incremental structural changes alter receptor selectivity and downstream signaling within a single peptide family. For laboratories building structure-activity datasets, this lineage is a useful framework, and MT-II typically anchors the non-selective end of that comparison. Documenting which analog and which batch were used in each experiment keeps such comparative datasets internally consistent and reproducible over time.
Related Research Guides
- PT-141 vs MT-II: Melanocortin Receptor Comparison
- How to Store Research Compounds Properly
- How to Reconstitute Lyophilized Compounds
- MT-II 10mg (research compound)
- Certificates of Analysis
Research Use Only. MT-II and all compounds referenced here are intended strictly for laboratory research by qualified professionals. They are not FDA approved and are not for human or animal use. Nothing in this article constitutes medical, therapeutic, or dosing guidance.
Storage & Handling
- Before reconstitution: store lyophilized vials at −20°C, protected from light and moisture.
- After reconstitution: refrigerate at 2–8°C and use within roughly 14–28 days; avoid freeze-thaw cycles.
- Recommended solvent: bacteriostatic water, handled under sterile technique.
Frequently Asked Questions
MT-II is studied in melanogenesis (pigmentation) research via MC1R, and in central neuroendocrine signaling via MC3R and MC4R. It also serves as a non-selective reference agonist in melanocortin receptor pharmacology.
PT-141 (bremelanotide) was derived from MT-II through structural modification to reduce MC1R pigmentation activity while retaining MC3R/MC4R affinity. MT-II remains non-selective, which is why the two are studied comparatively.
MT-II is a non-selective agonist across multiple melanocortin receptor subtypes, including MC1R, MC3R, and MC4R.
Store lyophilized vials at −20°C away from light and moisture. After reconstitution with bacteriostatic water, refrigerate at 2–8°C and avoid freeze-thaw cycles.
Research-grade MT-II is typically ≥99% pure by HPLC with a batch-specific COA documenting identity and purity.
Its non-selective engagement across melanocortin subtypes makes it a convenient baseline against which more selective analogs are compared in receptor-pharmacology studies.
Research Compounds
Research Use Only — Not for Human or Animal Consumption. Content is provided for informational and educational purposes and does not constitute medical advice.
Continue Your Research
Browse the full catalog of COA-verified research compounds.
Shop All Compounds →